Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR442970 · 3 trials · 3 indications
Clinical remission is based on modified Mayo subscores. The mMS ranges from 0 to 9 with higher scores indicating greater disease severity.
Endoscopic response is defined as decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) \>50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
The HiSCR50 was used for assessing HS treatment effectiveness in controlling inflammatory manifestations in the population. HiSCR50 was defined as \>=50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count. Baseline was defined as the last available value before the first dose of DB study drug. Percentages are rounded off to the tenth decimal place.
| Arm | Type | Description |
|---|---|---|
| SAR442970 Dose Regimen A | EXPERIMENTAL | Participants will receive SAR442970 dose regimen A |
| SAR442970 Dose Regimen B | EXPERIMENTAL | Participants will receive SAR442970 dose regimen B |
| Placebo | PLACEBO_COMPARATOR | Participants will receive SAR442970-matching placebo |
| SAR442970 | EXPERIMENTAL | Participants received SAR442970 once every two weeks (Q2W) in Period A (Day 1 to Week 16). Participants received SAR442970 Q2W in Period B (Up to Week 28). |
| Name | Type | Description |
|---|---|---|
| SAR442970 | DRUG | Route of administration: Subcutaneous |
| Placebo | DRUG | Route of administration: Subcutaneous |
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Male or female participants aged 18 to 75 years inclusive, at the time of signing the informed consent * Participants who have had clinical evidence of active UC for ≥3 months b...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
SAR442970 is an investigational small molecule being developed for Hidradenitis Suppurativa, Crohn's Disease, and Ulcerative Colitis. It is currently in Phase 2 clinical trials for these conditions.
SAR442970 is being developed by Sanofi, a company traded under the ticker SNY. Sanofi is conducting Phase 2 clinical trials for the drug in Hidradenitis Suppurativa, Crohn's Disease, and Ulcerative Colitis.
SAR442970 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing or completed for Hidradenitis Suppurativa, Crohn's Disease, and Ulcerative Colitis.
SAR442970 has three Phase 2 trials. NCT05849922, a completed study in Hidradenitis Suppurativa with 86 participants. NCT06958536, a recruiting study in Crohn's Disease with 99 participants. NCT06975722, a recruiting study in Ulcerative Colitis with 99 participants.
Yes, SAR442970 is being tested in Ulcerative Colitis. The Phase 2 trial NCT06975722 is recruiting adult participants with Ulcerative Colitis across multiple countries, including the United States, Australia, China, and Japan.
Yes, SAR442970 is being tested in Crohn's Disease. The Phase 2 trial NCT06958536 is recruiting adult participants with Crohn's Disease in countries such as the United States, Australia, Belgium, China, and Japan.